Sonrotoclax

HY-148026		
2383086-06	i-2	
C49H59N7O7S	5	
890.1		
Bcl-2 Famil	у	
Apoptosis		
Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month
	2383086-06 C ₄₉ H ₅₉ N ₇ O ₇ S 890.1 Bcl-2 Famil Apoptosis Powder	2383086-06-2 $C_{49}H_{59}N_7O_7S$ 890.1 Bcl-2 Family Apoptosis Powder -20°C 4°C In solvent -80°C

SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (1	12.35 mM; Need ultrasonic) Mass Solvent	1	-	10
Preparing Stock Solutions		Concentration	1 mg	5 mg	10 mg
		1 mM	1.1235 mL	5.6173 mL	11.2347 mL
		5 mM	0.2247 mL	1.1235 mL	2.2469 mL
	10 mM	0.1123 mL	0.5617 mL	1.1235 mL	
	Please refer to the so	lubility information to select the app	propriate solvent.		
In Vivo		one by one: 10% DMSO >> 40% PEC mL (2.81 mM); Clear solution; Need) >> 45% saline	
		one by one: 10% DMSO >> 90% (20 mL (2.81 mM); Clear solution; Need	. ,		
		one by one: 10% DMSO >> 90% cor mL (2.81 mM); Clear solution; Need			

BIOLOGICAL ACTIV	ИТҮ
Description	Sonrotoclax is a potent, orally active Bcl2 inhibitor. Sonrotoclax has effective cell killing effect against a variety of lymphoma and leukemia cell lines ^[1] .
In Vivo	Sonrotoclax (compound 1; 5-50 mg/kg; p.o.; daily, for 42 d; female NCG mice with acute lymphoblastic leukemia (ALL) xenografts) has antineoplastic activity and inhibits tumor growth ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.



Animal Model:	Female NCG mice with acute lymphoblastic leukemia (ALL) xenografts [[]
Dosage:	5, 15, 50 mg/kg
Administration:	oral administration; daily, for 42 days
Result:	Inhibited tumor growth in a dose-dependent manner.

REFERENCES

[1]. Nan HU, et, al. Methods of cancer treatment using bcl-2 inhibitor. WO2021110102A1.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA